| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | CICM cells and non-human mammalian embryos prepared by nuclear transfer of a proliferating differentiated cell or its nucleus | US08935052 | 1997-09-22 | US06235970B1 | 2001-05-22 | Steven L. Stice; Jose Cibelli; James Robl; Paul Golueke; F. Abel Ponce de Leon; D. Joseph Jerry |
| An improved method of nuclear transfer involving the transplantation of donor differentiated cell nuclei into enucleated oocytes of the same species as the donor cell is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring, and for production of isogenic CICM cells, including human isogenic embryonic or stem cells. Production of genetically engineered or transgenic mammalian embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated. | ||||||
| 162 | NON-HUMAN MAMMAL | US15531687 | 2015-12-02 | US20180255753A1 | 2018-09-13 | Osamu KAMINUMA; Kimiko INOUE; Kazufumi KATAYAMA; Atsuo OGURA |
| A non-human mammal and an offspring thereof, obtainable by a somatic cell nuclear transfer method using a nucleus of a CD4-positive T cell as a nuclear donor. The non-human mammal of the present invention surely and efficiently shows allergic reactions specific to various antigens that are shown to have associations with an immune allergic disease, such as mites and cedar pollens, so that the non-human mammal can be suitably used as the developmental models of allergic diseases for studies of various diseases by studying or pursuing possibilities of applications to the diseases. | ||||||
| 163 | Personalized production of biologics and method for reprogramming somatic cells | US15369776 | 2016-12-05 | US10030230B2 | 2018-07-24 | Theresa A. Deisher |
| Use invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation. | ||||||
| 164 | ARTIFICIAL OOCYTE ACTIVATION | US15726672 | 2017-10-06 | US20180094240A1 | 2018-04-05 | Kiho Lee; Randall S. Prather |
| The present invention provides novel methods for improving the efficiency of artificial activation of unfertilized mammalian oocytes by reducing the intracellular concentration of Zn2+ in the oocyte. The methods of the invention may additionally comprise a preceding step of increasing the intracellular concentration of Ca2+ in the oocyte prior to reduction of the intracellular Zn2+ concentration. The invention further provides unfertilized oocytes activated by the disclosed methods and viable mammalian animals produced from unfertilized oocytes activated by the disclosed methods. | ||||||
| 165 | Artificial oocyte activation | US14554504 | 2014-11-26 | US09783779B2 | 2017-10-10 | Kiho Lee; Randall S. Prather |
| The present invention provides novel methods for improving the efficiency of artificial activation of unfertilized mammalian oocytes by reducing the intracellular concentration of Zn2+ in the oocyte. The methods of the invention may additionally comprise a preceding step of increasing the intracellular concentration of Ca2+ in the oocyte prior to reduction of the intracellular Zn2+ concentration. The invention further provides unfertilized oocytes activated by the disclosed methods and viable mammalian animals produced from unfertilized oocytes activated by the disclosed methods. | ||||||
| 166 | SOMATIC CELL NUCLEAR TRANSFER METHODS | US14775594 | 2014-03-14 | US20160024528A1 | 2016-01-28 | Dietrich M. Egli |
| The present invention provides methods for making reconstructed diploid human oocytes comprising the diploid genome of a human somatic cell, and also methods for making human nuclear transfer embryos, human embryonic stem cells, and human differentiated cells therefrom. The present invention also provides reconstructed human oocytes, human nuclear transfer embryos, human embryonic stem cells, and differentiated cells made using such methods, as well as compositions and kits useful in performing such methods. | ||||||
| 167 | Method for Generating Immune-Compatible Cells and Tissues Using Nuclear Transfer Techniques | US13108666 | 2011-05-16 | US20120246746A1 | 2012-09-27 | Robert Lanza; Michael West |
| This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues. | ||||||
| 168 | Method for preparing fish embryos | US12224284 | 2006-02-24 | US08258369B2 | 2012-09-04 | Yuko Wakamatsu; Kenjiro Ozato |
| An object of the invention is to effectively prepare a fish embryo with a correct chromosomal ploidy by nuclear transplantation in which an exogenous fish nucleus is transplanted in a cytoplasmic recipient. For this object, the invention comprises a step of preparing a fish embryo by transplanting a fish cell nucleus to an unfertilized egg. The step of preparing a fish embryo comprises a step of imposing physical and/or chemical stress to the unfertilized egg after activation. By imposing such stress, the stage of haplosis in a female nucleus which happens at the early stage of a series of developmental steps occurring in an unfertilized egg is suppressed and the correct ploidy of an obtained embryo is at least secured. | ||||||
| 169 | SIMPLIFIED METHOD FOR PARTIAL GENETIC AND EPIGENETIC REPROGRAMMING OF CELLS | US13146158 | 2010-01-07 | US20110287536A1 | 2011-11-24 | Fred Zacouto |
| A method of partial, rapid and direct genetic and epigenetic reprogramming of biological cells without returning to the embryonic state can partially reprogram a cell to be treated to specifically modify the biological age of said cell to be treated without causing functional de-differentiation of said cell to be treated, said cell to be treated always remaining as a specialized functional cell that is immunologically autologous to the donor tissue from which said cell to be treated is derived, and for which the phenotype is preserved and/or rejuvenated. | ||||||
| 170 | METHOD OF CONSTRUCTING CLONE MAMMAL | US11573995 | 2005-08-01 | US20100083393A1 | 2010-04-01 | Hiroshi Wakao; Akihiko Koseki; Masaru Taniguchi; Atsuo Ogura; Kimiko Inoue |
| The present invention provides a method of producing a cloned mammal, which uses a mammalian natural killer T cell as a donor cell, a cloned mammal obtained by the method, a method of obtaining an ES cell from the embryo of the cloned animal and an ES cell obtained by the method. | ||||||
| 171 | METHODS FOR MAKING AND USING REPROGRAMMED HUMAN SOMATIC CELL NUCLEI AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS | US12212557 | 2008-09-17 | US20090137040A1 | 2009-05-28 | Jose Cibelli; Michael West; Keith Campbell |
| Activated human embryos produced by therapeutic cloning can give rise to human totipotent and pluripotent stem cells from which autologous cells for transplantation therapy are derived. The present invention provides methods for producing activated human embryos that can be used to generate totipotent and pluripotent stem cells from which autologous cells and tissues suitable for transplantation can be derived. In one embodiment, the invention provides methods for producing activated human embryos by parthenogenesis; in another embodiment, the invention provides methods for producing activated human embryos by somatic cell nuclear transfer whereby the genetic material of a differentiated human donor cell is reprogrammed to form a diploid human pronucleus capable of directing a cell to generate the stem cells from which autologous, isogenic cells for transplantation therapy are derived. The ability to create autologous human embryos represents a critical step towards generating immune-compatible stem cells that can be used to overcome the problem of immune rejection in regenerative medicine. The activated human embryos produced by the present invention also provide model systems for identifying and analyzing the molecular mechanisms of epigenetic imprinting and the genetic regulation of embryogenesis and development. | ||||||
| 172 | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease | US11529720 | 2006-09-26 | US20090092588A1 | 2009-04-09 | Steven Stice; Jose Cibelli; James Robl; Paul Golueke; F. Abel Ponce De Leon; D. Joseph Jerry |
| Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease. | ||||||
| 173 | PRIMATE TOTIPOTENT AND PLURIPOTENT STEM CELLS PRODUCED BY SOMATIC CELL NUCLEAR TRANSFER | US12122557 | 2008-05-16 | US20090004740A1 | 2009-01-01 | Shoukhrat M. Mitalipov; Don P. Wolf; James Byrne |
| Purified totipotent stem cells and pluripotent stems cells derived by somatic cell nuclear transfer are disclosed herein, as well as cell lines, multipotent cells and differentiated cells produced from these stem cells. The stem cells are produced from an enucleated host cell from a first donor and nuclear genetic material from a somatic cell of a second donor. Methods for making and using such compositions of such stem cells are also provided. | ||||||
| 174 | Cloning B and T lymphocytes | US11890127 | 2007-08-02 | US20070274954A1 | 2007-11-29 | Michael West |
| This invention includes methods for producing non-human mammals expressing monoclonal or oligoclonal B or T lymphocytes, as well as embryonic and hematopoietic stem cells that differentiate into monoclonal or oligoclonal B or T cells, using cloning by nuclear transfer with a B or T cell of interest as the nuclear donor cell. | ||||||
| 175 | Telomerizing nuclear donor cells and improving the efficiency on nuclear transfer | US10105616 | 2002-03-21 | US07265262B2 | 2007-09-04 | A. John Clark; Wei Cui; Chris Denning; Debbiao Zhao |
| This disclosure provides a system for creating cloned cells and embryos that are genetically modified. Cells are treated to increase expression of telomerase and potentially extend replicative capacity. One or more genetic modifications is made to inactivate a gene or confer desirable features, growing and selecting the cells as needed. The modified nucleus can then be transferred to a suitable recipient cell, which can then be used to grow an embryo with the conferred attributes. This technology makes it possible to create embryos, animals and embryonic cell lines with multiple genetic modifications, including homozygously inactivated genes and gene substitutions. | ||||||
| 176 | Endothelial precursor cells for enhancing and restoring vascular function | US10367639 | 2003-02-13 | US07135171B2 | 2006-11-14 | Jay Edelberg; Shahin Rafii; Mun Hong; Robert P. Lanza; Michael D. West |
| The invention provides methods of treating and preventing loss of tissue vascularization that can occur, for example, upon aging. | ||||||
| 177 | Embryonically modified animal and method of constructing the same | US10505862 | 2003-02-27 | US20060236416A1 | 2006-10-19 | Yasumitsu Nagao; Hiroshi Imai; Takuro Horii; Yoshikazu Totsuka |
| The present invention relates to a method for efficiently producing a reproducible animal using totipotent cells wherein mitochondrial DNAs (e.g., wild-type DNAs) adapted to nuclear DNAs have been introduced into or substituted with mitochondrial DNAs, and the present invention also relates to an animal obtained by such production method. When the totipotent cells are ES cells derived from an inbred mouse, the tetraploid rescue method is preferably used. In the production of chimeric animals, mitochondrial DNAs of totipotent cells derived from an animal to be used is substituted with wild-type mitochondrial DNAs by the back-crossing method, the nuclear replacement method, or the like, and the cells are injected into a tetraploid fertilized egg, so that a reproducible inbred chimeric animal is produced while avoiding death of the obtained inbred chimeric animal from respiratory disturbances and the like immediately after birth. The thus obtained reproducible chimeric animal can be used for gene function analyses, animal experiments, and the like without carrying out complicated manipulations for generating inbred animals. | ||||||
| 178 | Method for treating inflammatory disorders | US11292007 | 2005-12-02 | US20060123501A1 | 2006-06-08 | Robert Korneluk; Martin Holcik; Damiano Conte; Charles Lefebvre; Eric LaCasse |
| The invention features a method of treating an inflammatory disorder, such as sepsis, in a subject. The method involves administering to the subject an antagonist of cIAP2 expression and/or function, so that the disorder is treated. | ||||||
| 179 | Methods of prescreening cells for nuclear transfer procedures | US11081945 | 2005-03-16 | US20060123500A1 | 2006-06-08 | Yann Echelard; Li-How Chen |
| The present invention provides for the production of transgenic animals through pre-screening methods designed to improve the efficiency of nuclear transfer and consequentially the production characteristics of transgenic mammals relative to proteins of interest. The invention is thus useful in the production of transgenic ungulate animals capable of producing desired biopharmaceuticals in their milk at higher yield than a comparable heterzygote or producing animals with better physiological attributes. | ||||||
| 180 | Animal models | US10521319 | 2003-07-17 | US20060123496A1 | 2006-06-08 | Edward Blair; Neil Clarke; Sebastian Johnston; David Rowlands |
| A transgenic non-human animal whose genome comprises a polynucleotide encoding human ICAM-1 domains D1 and D2 and preferably encoding human ICAM-1 domains D1 and D2 and host non-human ICAM-1 domains D3, D4 and D5. Methods for the production of such transgenic animals, screening methods using such transgenic animals, associated transgenes, constructs, vectors, and cells are disclosed. The transgenic non-human animal is a suitable model for studying human rhinovirus infection. | ||||||
QQ群二维码
意见反馈
意见反馈